Cargando…

Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma

BACKGROUND: Accurate prognosis assessment is essential for surgically resected intrahepatic cholangiocarcinoma (ICC) while published prognostic tools are limited by modest performance. We therefore aimed to establish a novel model to predict survival in resected ICC based on readily-available clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Gu-Wei, Jiao, Chen-Yu, Xu, Zheng-Gang, Li, Xiang-Cheng, Wang, Ke, Wang, Xue-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915487/
https://www.ncbi.nlm.nih.gov/pubmed/35277130
http://dx.doi.org/10.1186/s12885-022-09352-3
_version_ 1784668034154102784
author Ji, Gu-Wei
Jiao, Chen-Yu
Xu, Zheng-Gang
Li, Xiang-Cheng
Wang, Ke
Wang, Xue-Hao
author_facet Ji, Gu-Wei
Jiao, Chen-Yu
Xu, Zheng-Gang
Li, Xiang-Cheng
Wang, Ke
Wang, Xue-Hao
author_sort Ji, Gu-Wei
collection PubMed
description BACKGROUND: Accurate prognosis assessment is essential for surgically resected intrahepatic cholangiocarcinoma (ICC) while published prognostic tools are limited by modest performance. We therefore aimed to establish a novel model to predict survival in resected ICC based on readily-available clinical parameters using machine learning technique. METHODS: A gradient boosting machine (GBM) was trained and validated to predict the likelihood of cancer-specific survival (CSS) on data from a Chinese hospital-based database using nested cross-validation, and then tested on the Surveillance, Epidemiology, and End Results (SEER) database. The performance of GBM model was compared with that of proposed prognostic score and staging system. RESULTS: A total of 1050 ICC patients (401 from China and 649 from SEER) treated with resection were included. Seven covariates were identified and entered into the GBM model: age, tumor size, tumor number, vascular invasion, number of regional lymph node metastasis, histological grade, and type of surgery. The GBM model predicted CSS with C-Statistics ≥ 0.72 and outperformed proposed prognostic score or system across study cohorts, even in sub-cohort with missing data. Calibration plots of predicted probabilities against observed survival rates indicated excellent concordance. Decision curve analysis demonstrated that the model had high clinical utility. The GBM model was able to stratify 5-year CSS ranging from over 54% in low-risk subset to 0% in high-risk subset. CONCLUSIONS: We trained and validated a GBM model that allows a more accurate estimation of patient survival after resection compared with other prognostic indices. Such a model is readily integrated into a decision-support electronic health record system, and may improve therapeutic strategies for patients with resected ICC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09352-3.
format Online
Article
Text
id pubmed-8915487
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89154872022-03-18 Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma Ji, Gu-Wei Jiao, Chen-Yu Xu, Zheng-Gang Li, Xiang-Cheng Wang, Ke Wang, Xue-Hao BMC Cancer Research BACKGROUND: Accurate prognosis assessment is essential for surgically resected intrahepatic cholangiocarcinoma (ICC) while published prognostic tools are limited by modest performance. We therefore aimed to establish a novel model to predict survival in resected ICC based on readily-available clinical parameters using machine learning technique. METHODS: A gradient boosting machine (GBM) was trained and validated to predict the likelihood of cancer-specific survival (CSS) on data from a Chinese hospital-based database using nested cross-validation, and then tested on the Surveillance, Epidemiology, and End Results (SEER) database. The performance of GBM model was compared with that of proposed prognostic score and staging system. RESULTS: A total of 1050 ICC patients (401 from China and 649 from SEER) treated with resection were included. Seven covariates were identified and entered into the GBM model: age, tumor size, tumor number, vascular invasion, number of regional lymph node metastasis, histological grade, and type of surgery. The GBM model predicted CSS with C-Statistics ≥ 0.72 and outperformed proposed prognostic score or system across study cohorts, even in sub-cohort with missing data. Calibration plots of predicted probabilities against observed survival rates indicated excellent concordance. Decision curve analysis demonstrated that the model had high clinical utility. The GBM model was able to stratify 5-year CSS ranging from over 54% in low-risk subset to 0% in high-risk subset. CONCLUSIONS: We trained and validated a GBM model that allows a more accurate estimation of patient survival after resection compared with other prognostic indices. Such a model is readily integrated into a decision-support electronic health record system, and may improve therapeutic strategies for patients with resected ICC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09352-3. BioMed Central 2022-03-11 /pmc/articles/PMC8915487/ /pubmed/35277130 http://dx.doi.org/10.1186/s12885-022-09352-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ji, Gu-Wei
Jiao, Chen-Yu
Xu, Zheng-Gang
Li, Xiang-Cheng
Wang, Ke
Wang, Xue-Hao
Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma
title Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma
title_full Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma
title_fullStr Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma
title_full_unstemmed Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma
title_short Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma
title_sort development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915487/
https://www.ncbi.nlm.nih.gov/pubmed/35277130
http://dx.doi.org/10.1186/s12885-022-09352-3
work_keys_str_mv AT jiguwei developmentandvalidationofagradientboostingmachinetopredictprognosisafterliverresectionforintrahepaticcholangiocarcinoma
AT jiaochenyu developmentandvalidationofagradientboostingmachinetopredictprognosisafterliverresectionforintrahepaticcholangiocarcinoma
AT xuzhenggang developmentandvalidationofagradientboostingmachinetopredictprognosisafterliverresectionforintrahepaticcholangiocarcinoma
AT lixiangcheng developmentandvalidationofagradientboostingmachinetopredictprognosisafterliverresectionforintrahepaticcholangiocarcinoma
AT wangke developmentandvalidationofagradientboostingmachinetopredictprognosisafterliverresectionforintrahepaticcholangiocarcinoma
AT wangxuehao developmentandvalidationofagradientboostingmachinetopredictprognosisafterliverresectionforintrahepaticcholangiocarcinoma